Pediatrix posted strong adjusted earnings, but growth relies heavily on pricing and share repurchases as core patient volumes continue to slide.
Pediatrix reported improved adjusted earnings per share and reaffirmed EBITDA guidance, but declining same-unit patient volumes and rising costs raise sustainability concerns.
Pediatrix Medical Group reported second-quarter adjusted EPS of $0.63, up from $0.53, driven by favorable reimbursement rates and aggressive share buybacks. Despite the headline growth, same-unit patient volumes fell across core services, including a 3.2% decline in neonatal intensive care days, raising concerns about the long-term sustainability of current earnings momentum.
Earnings growth is primarily driven by improved reimbursement rates, a shift toward higher-paying commercial payors, and a significant reduction in the weighted average share count through buybacks.
As of mid-September, the stock trades at a forward price-to-earnings ratio of 8.21, suggesting the market remains skeptical of future growth prospects.